Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves First Anti-PDL1 Cancer Immunotherapy for Metastatic Lung Cancer

XTALKS VITALS NEWS

Lung Cancer

The anti-PDL1 cancer immunotherapy is indicated for patients with tumors containing EGFR or ALK gene abnormities, and those who have experienced disease progression following platinum-containing chemotherapy.

Tweetables from this article:

Tweet: Patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel #chemotherapy http://ctt.ec/_Xe84+ Patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel chemotherapy.

Share this!

October 20, 2016 | by Sarah Hand, M.Sc.

Roche’s biotechnology division, Genentech, has just received US Food and Drug Administration (FDA) approval for their non-small cell lung cancer drug, Tecentriq (atezolizumab). The anti-PDL1 cancer immunotherapy is indicated for patients with tumors containing EGFR or ALK gene abnormities, and those who have experienced disease progression following platinum-containing chemotherapy.

The FDA approval was based on data collected during a Phase II clinical trial – dubbed POPLAR – along with a Phase II study, known as OAK. In the OAK clinical trial, patients taking Tecentriq lived 4.2 months longer than those treated with the standard docetaxel chemotherapy.

“Tecentriq is a new option to help people with this type of previously treated metastatic lung cancer, regardless of PD-L1 expression, live longer than chemotherapy,” said Dr. Sandra Horning, chief medical officer and head of global product development for Genentech. “Tecentriq is the first and only approved cancer immunotherapy designed to target the PD-L1 protein, which may play an important role in the way the medicine works.”



The OAK clinical trial enrolled patients with both squamous and non-squamous types of lung cancer, and did not discriminate based on PD-L1 status. In all, over 15 clinical trials have been conducted to assess Tecentriq, including seven Phase III studies using the immunotherapy as a possible first-line treatment for lung cancer.

Tecentriq is a monoclonal antibody which binds to the PD-L1 protein expressed on certain tumor cells. As an immunotherapy, the drug is designed to stimulate the activation of T cells to detect and destroy cancer cells. The Phase III OAK clinical trial is a global, multicenter, open-label, randomized, controlled study, which compared the safety and efficacy of Tecentriq compared to docetaxel, in 1,225 patients with NSCLC.

“Over the past 15 years, survival rates for advanced lung cancer have been consistently improving,” said Bonnie J. Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (ALCF). “The approval of Tecentriq is another important step for patients by increasing the number of medicines available to people living with lung cancer.”

Over 224,000 Americans will be diagnosed with lung cancer this year, according to statistics from the American Cancer Society. NSCLC accounts for almost 85 percent of lung cancer cases, with many diagnoses being made once the disease has entered the most advanced stages.


Keywords: Lung Cancer, Immunotherapy, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
German Merck Launches Spinoff Immuno-Oncology Company

June 22, 2017 - Merck KGaA has announced the launch of iOnctura SA, a new immuno-oncology company built around two assets from the Healthcare R&D portfolio of the pharmaceutical company.

Featured In: Biotech News


Ikea Promotes Food Products by Offering Fill-in-the-Blanks Recipe Sheets

June 21, 2017 - In an effort to promote the company’s food business, Ikea recently launched a set of recipes printed on parchment paper that encourage consumers to “fill-in-the-blanks” with ingredients, fold the paper and cook the bag in the oven.

Featured In: Food News


Nanomaterial Promotes Bone Growth after Spinal Fusion Surgery

June 21, 2017 - Researchers at Northwestern University have developed a bioactive nanomaterial capable of effectively stimulating bone regeneration after spinal fusion surgery.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Drug Development During the Last Week

REGISTER FOR THESE WEBINARS

Serialized? Yes. But are Products Still Being Diverted?


Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors


Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model


Imaging-based Subtypes of Pancreatic Cancer


Copyright © 2016-2017 Honeycomb Worldwide Inc.